DFX Intelligence

Data Factory

Private equityFirmbuyoutmiddle market

Ampersand Capital Partners

Private Equity

Boston, MA

Ampersand Capital Partners is a life sciences and healthcare-focused private equity firm with decades of experience forging leaders in life sciences.

This is the graph view. The full profile, with its team, deals and sources, is on Private Equity.Open the full profile →

Search this name across graphsid dfx:pe:022cbdb3-6a58-42fb-8931-eaa62207175e

Data as of Sep 16, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures, news and newswire. Page built Sep 18, 2026, 11:43 PM UTC and rebuilt at most every 15 minutes.

Relationships: 156
Dated events: 22
On other graphs: 2
Observed: Sep 13, 2026 to Sep 16, 2026
37 observations

Across DFX

same identity by shared identifier, citation, or a bridge measured by hand

Independent Sponsorsidentity

Ampersand Capital Partners

Capital provider to sponsors · shared crd

RIA / Wealth Managementidentity

AMPERSAND CAPITAL PARTNERS

Registered adviser · shared crd

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Funds: 9
PE funds: 9
Vintages: 2001 to 2022
PE GAV, 2024 filing: $2.8Bgross asset value on Form ADV; never dry powder
Regulatory AUM: $2.8B
Investments: 79
Active investments: 52
Size band: MIDDLE MARKETderivedproxy: $2.79bn Private Equity Fund GAV on the Form ADV filed 2024-08-19
Stated sectors: life_sciences,technology
Stated control: minority
Latest ADV filing: Aug 19, 2024
Employees (ADV): 32
Website: ampersandcapital.com

Funds

Fund	Vintage	Lifecycle	ADV type	Form D sold	GAV
Ampersand 2022 Limited Partnership	2022	Unknown	Private Equity Fund	n/a	$1.2B
Ampersand Cf Limited Partnership	2021	Active deployment	Private Equity Fund	n/a	$443M
Ampersand 2020 Limited Partnership	2020	Mature	Private Equity Fund	n/a	$658M
Ampersand 2018 Limited Partnership	2018	Harvest	Private Equity Fund	n/a	$447M
Ampersand 2014 Limited Partnership	2014	Harvest	Private Equity Fund	n/a	$7.9M
Ampersand 2011 Limited Partnership	2011	Wound down	Private Equity Fund	n/a	$1.7M
Ampersand 2006 Limited Partnership	2006	Wound down	Private Equity Fund	n/a	$1.9M
Ampersand 2001 Limited Partnership	2001	Wound down	Private Equity Fund	n/a	$470,003
Ampersand 2001 Companion Fund Limited Partnership	2001	Wound down	Private Equity Fund	n/a	$25,754

Investments

Company	State	Role	Control	Invested	Exited	Status
CartiHeal	n/a	Add on	control	Apr 4, 2022	n/a	active
Adaptas Solutions	n/a	unknown	unknown	n/a	n/a	exited
Admera Health	n/a	unknown	unknown	n/a	n/a	active
Agilux Laboratories	n/a	unknown	unknown	n/a	n/a	exited
Alcami Corporation	n/a	unknown	unknown	n/a	n/a	active
AnaBios	n/a	unknown	unknown	n/a	n/a	active
ANI Pharmaceuticals	n/a	unknown	unknown	n/a	n/a	active
Arranta Bio	n/a	unknown	unknown	n/a	n/a	exited
Avid Bioservices	n/a	unknown	unknown	n/a	n/a	active
Avista Pharma Solutions	n/a	unknown	unknown	n/a	n/a	exited
Bako Diagnostics	n/a	unknown	unknown	n/a	n/a	exited
Beacon Intelligence	n/a	unknown	unknown	n/a	n/a	active
BioClinica	n/a	unknown	unknown	n/a	n/a	exited
Biologos	n/a	unknown	unknown	n/a	n/a	active
Biosynth	n/a	unknown	unknown	n/a	n/a	active
Bioventus	n/a	unknown	unknown	n/a	n/a	active
Priority Solutions	n/a	unknown	unknown	n/a	n/a	exited
Canopy Biosciences	n/a	unknown	unknown	n/a	n/a	exited
Confluent Medical Technologies	n/a	unknown	unknown	n/a	n/a	active
CRI Lifetree	n/a	unknown	unknown	n/a	n/a	exited
CurTec	n/a	unknown	unknown	n/a	n/a	active
CutisPharma	n/a	unknown	unknown	n/a	n/a	exited
Dynex Technologies	n/a	unknown	unknown	n/a	n/a	exited
Elite One Source	n/a	unknown	unknown	n/a	n/a	exited
Flagship Biosciences	n/a	unknown	unknown	n/a	n/a	active
Gannet BioChem	n/a	unknown	unknown	n/a	n/a	active
GenDx	n/a	unknown	unknown	n/a	n/a	exited
Genewiz	n/a	unknown	unknown	n/a	n/a	exited
Genezen	n/a	unknown	unknown	n/a	n/a	active
Genoptix	n/a	unknown	unknown	n/a	n/a	exited

Relationships

showing 80 of 156

Invested in (18)

→ CartiHealCompanyAdd on
Apr 4, 2022 to presentfactNews and newswire
→ Bioventus Exercises Call OptionCompanyplatform
factNews and newswire
→ ProtaGeneCompanyunknown
factThe subject's own site
→ The Resolian StoryCompanyunknown
factThe subject's own site
→ Stefan Beyer: The Vibalogics StoryCompanyunknown
factThe subject's own site
→ Mark Bamforth: The Brammer Bio StoryCompanyunknown
factThe subject's own site
→ Jay Ray: The Adaptas Solutions StoryCompanyunknown
factThe subject's own site
→ Peter Li & Jean Qiu: The Nexcelom StoryCompanyunknown
factThe subject's own site
→ Benoit Bouche: The Nexelis StoryCompanyunknown
factThe subject's own site
→ Amy Liao: The GENEWIZ StoryCompanyunknown
factThe subject's own site
→ Pat Walsh: The Alcami StoryCompanyunknown
factThe subject's own site
→ Dean Schauer: The Confluent StoryCompanyunknown
factThe subject's own site
→ Laboratory ProductsCompanyunknown
factThe subject's own site
→ Laboratory ServicesCompanyunknown
factThe subject's own site
→ Contract ManufacturingCompanyunknown
factThe subject's own site
→ Pharma ServicesCompanyunknown
factThe subject's own site
→ Specialty ProductsCompanyunknown
factThe subject's own site
→ Adaptas SolutionsCompanyunknown
factThe subject's own site

Employs (62)

→ David WeberPersonExecutive Advisor
factThe subject's own site
→ Cole S. AldrichPersonSenior Associate
factThe subject's own site
→ Natalia C. AndersonPersonSenior Manager, Compliance
factThe subject's own site
→ David Q. AndersonPersonGeneral Partner
factThe subject's own site
→ Stuart A. AuerbachPersonAdvisory Partner
factThe subject's own site
→ Kristine C. AustinPersonExecutive Assistant
factThe subject's own site
→ Mark R. BamforthPersonExecutive Advisor
factThe subject's own site
→ Stefan BeyerPersonExecutive Advisor
factThe subject's own site
→ Benoit P. BouchePersonOperating Partner
factThe subject's own site
→ Isabel S. BrooksPersonSenior Associate
factThe subject's own site
→ Madeline Brown-SchererPersonManager, Business Development
factThe subject's own site
→ Steven J. ChangPersonFinance Manager
factThe subject's own site
→ Richard Alan CharpiePersonFounder
factThe subject's own site
→ Justin K. ChoiPersonAssociate
factThe subject's own site
→ Olivia M. CianoPersonFund Accountant
factThe subject's own site
→ Steven M. DalePersonSenior Manager, Accounting
factThe subject's own site
→ Emanuele M. DelfinoPersonAssociate
factThe subject's own site
→ Henry DubinaPersonExecutive Advisor
factThe subject's own site
→ Melanie M. FanPersonPartner
factThe subject's own site
→ Steve FavaloroPersonExecutive Advisor
factThe subject's own site
→ Nicolas S. GianelliPersonSenior Associate
factThe subject's own site
→ Julie F. GilesPersonController
factThe subject's own site
→ Aditya V. GoelPersonAssociate
factThe subject's own site
→ Herb H. HooperPersonManaging Partner
factThe subject's own site
→ Jonathan HuntPersonExecutive Advisor
factThe subject's own site
→ Thomas de JagerPersonVice President, Business Development
factThe subject's own site
→ Peter H. JamiesonPersonVice President, Data & AI
factThe subject's own site
→ Maxwell R. KeeleyPersonVice President
factThe subject's own site
→ Hidde Van KerckhovenPersonPrincipal
factThe subject's own site
→ Elias J. LaimboeckPersonSenior Associate
factThe subject's own site
and 32 more

Dated events

14 bookkeeping events (roster, classification and holdings changes) folded below

Occurred
Jun 30, 2026
Firm news
News Read More June 30, 2026 Corten Capital and Ampersand Capital Partners Complete Acquisition of Beacon Intelligence to Accelerate Growth in Life Sciences R&D Intelligence Ampersand News
The subject's own siteobserved 3 days ago
Occurred
Jun 4, 2026
Firm news
News Read More June 4, 2026 Purna Pharmaceuticals Names Marc Verbruggen as Managing Director Portfolio Company News
The subject's own siteobserved 3 days ago
Occurred
May 28, 2026
Firm news
News Read More May 28, 2026 Ampersand Closes Oversubscribed Fund at $1.5 Billion Hard Cap Ampersand News
The subject's own siteobserved 3 days ago
Occurred
Apr 4, 2022
Transaction announced
Bioventus Exercises Call Option to Acquire CartiHeal
News and newswireobserved 3 days ago
Occurred
Mar 31, 2021
Person left
Loretta Mcclary (Director Of Tax, Compliance Administrator) no longer on Schedule A of Ampersand Capital Partners
Form ADVobserved 5 days ago
Occurred
Mar 28, 2014
Person left
J. David Jacobs (General Counsel; Chief Legal Officer) no longer on Schedule A of Ampersand Capital Partners
Form ADVobserved 5 days ago
Occurred
Jan 1, 2013
Person joined
Dana L Niles joined Schedule A of Ampersand Capital Partners as Cfo; Chief Compliance Officer
Form ADVobserved 5 days ago
Occurred
Feb 14, 2012
Adviser first adv filing
Ampersand Capital Partners first filed Form ADV in the extract (IA)
Form ADVobserved 5 days ago

Show 14 bookkeeping events

Occurred
Mar 30, 2026
Ampersand Capital Partners: Private Equity Funds on Form ADV 5 (2024 extract) -> 4 (roster 2026-09-01)
Occurred
Mar 28, 2024
Fund 805-6724043809 no longer reported on Form ADV by Ampersand Capital Partners
Occurred
Mar 28, 2024
Fund 805-2731610693 no longer reported on Form ADV by Ampersand Capital Partners
Occurred
Mar 28, 2024
Fund 805-6109777506 no longer reported on Form ADV by Ampersand Capital Partners
Occurred
Mar 28, 2024
Fund 805-8778085835 no longer reported on Form ADV by Ampersand Capital Partners
Occurred
Mar 31, 2023
Ampersand 2022 Limited Partnership first reported on Form ADV by Ampersand Capital Partners (Private Equity Fund), GAV $1,237,113,403
Occurred
Mar 31, 2021
Ampersand Cf Limited Partnership first reported on Form ADV by Ampersand Capital Partners (Private Equity Fund), GAV $635,798,056
Occurred
Mar 30, 2020
Ampersand 2020 Limited Partnership first reported on Form ADV by Ampersand Capital Partners (Private Equity Fund)
Occurred
Mar 30, 2018
Ampersand 2018 Limited Partnership first reported on Form ADV by Ampersand Capital Partners (Private Equity Fund)
Occurred
Mar 28, 2014
Ampersand 2014 Limited Partnership first reported on Form ADV by Ampersand Capital Partners (Private Equity Fund)
Occurred
Feb 14, 2012
Ampersand 2001 Limited Partnership first reported on Form ADV by Ampersand Capital Partners (Private Equity Fund), GAV $147,410,795
Occurred
Feb 14, 2012
Ampersand 2011 Limited Partnership first reported on Form ADV by Ampersand Capital Partners (Private Equity Fund), GAV $63,307,882
Occurred
Feb 14, 2012
Ampersand 2001 Companion Fund Limited Partnership first reported on Form ADV by Ampersand Capital Partners (Private Equity Fund), GAV $1,825,508
Occurred
Feb 14, 2012
Ampersand 2006 Limited Partnership first reported on Form ADV by Ampersand Capital Partners (Private Equity Fund), GAV $173,839,310

Who to call

the organisation, the role and the published line, with the filing or website that published it; revealed to signed-in accounts

The firm's published line

Revealable: 1 business phone (Form ADV), 1 office address (Form ADV), 1 website (Form ADV) · as of 2026-09-13

David Weber
Executive Advisor · Revealable: 1 professional profile (firm website)
Cole S. Aldrich
Senior Associate · Revealable: 1 professional profile (firm website)
Natalia C. Anderson
Senior Manager, Compliance · Revealable: 1 professional profile (firm website)
David Q. Anderson
General Partner · Revealable: 1 professional profile (firm website)
Stuart A. Auerbach
Advisory Partner · Revealable: 1 professional profile (firm website)
Kristine C. Austin
Executive Assistant · Revealable: 1 professional profile (firm website)
Mark R. Bamforth
Executive Advisor · Revealable: 1 professional profile (firm website)
Stefan Beyer
Executive Advisor · Revealable: 1 professional profile (firm website)
Benoit P. Bouche
Operating Partner · Revealable: 1 professional profile (firm website)
Isabel S. Brooks
Senior Associate · Revealable: 1 professional profile (firm website)
Madeline Brown-Scherer
Manager, Business Development · Revealable: 1 professional profile (firm website)
Steven J. Chang
Finance Manager · Revealable: 1 professional profile (firm website)
Richard Alan Charpie
Founder · Revealable: 1 professional profile (firm website)
Justin K. Choi
Associate · Revealable: 1 professional profile (firm website)
Olivia M. Ciano
Fund Accountant · Revealable: 1 professional profile (firm website)
Steven M. Dale
Senior Manager, Accounting · Revealable: 1 professional profile (firm website)
Emanuele M. Delfino
Associate · Revealable: 1 professional profile (firm website)
Henry Dubina
Executive Advisor · Revealable: 1 professional profile (firm website)
Melanie M. Fan
Partner · Revealable: 1 professional profile (firm website)
Steve Favaloro
Executive Advisor · Revealable: 1 professional profile (firm website)
Nicolas S. Gianelli
Senior Associate · Revealable: 1 professional profile (firm website)
Julie F. Giles
Controller · Revealable: 1 professional profile (firm website)
Aditya V. Goel
Associate · Revealable: 1 professional profile (firm website)
Herb H. Hooper
Managing Partner · Revealable: 1 professional profile (firm website)
Jonathan Hunt
Executive Advisor · Revealable: 1 professional profile (firm website)
Thomas de Jager
Vice President, Business Development · Revealable: 1 professional profile (firm website)
Peter H. Jamieson
Vice President, Data & AI · Revealable: 1 professional profile (firm website)
Maxwell R. Keeley
Vice President · Revealable: 1 professional profile (firm website)
Hidde Van Kerckhoven
Principal · Revealable: 1 professional profile (firm website)
Elias J. Laimboeck
Senior Associate · Revealable: 1 professional profile (firm website)
Lauren E. Lange
Associate · Revealable: 1 professional profile (firm website)
Eric B. Lev
General Partner · Revealable: 1 professional profile (firm website)
Peter Li
Executive Advisor · Revealable: 1 professional profile (firm website)
Gregory W. Magoon
Vice President · Revealable: 1 professional profile (firm website)
Nicole R. Manning
Executive Assistant · Revealable: 1 professional profile (firm website)
Laurence R. McCarthy
Operating Partner · Revealable: 1 professional profile (firm website)
Arya Mehrabanzad
Principal · Revealable: 1 professional profile (firm website)
Jenna N. Melvin
Senior Manager, Business Development · Revealable: 1 professional profile (firm website)
Peter K. Messervy
Analyst, Business Development · Revealable: 1 professional profile (firm website)
Matthew A. Munfakh
Vice President · Revealable: 1 professional profile (firm website)

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Provenance

Graph: Private Equity
Canonical id: dfx:pe:022cbdb3-6a58-42fb-8931-eaa62207175e
First observed: Sep 13, 2026
Last observed: Sep 16, 2026 2 days ago
Source families: Federal regulator filings, Firm and issuer disclosures, News and newswire
4 registered feeds stand behind this record; each fact above carries its own dates and, where the publisher serves one, its document.
Resolution: Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.